(IAK) iShares U.S. Insurance - Ratings and Ratios

Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US4642887867 • Financial

IAK: Insurance, Stocks, Futures, Options, Swaps

The iShares U.S. Insurance ETF (NYSE ARCA: IAK) is designed to provide exposure to the U.S. insurance sector by tracking the performance of its underlying index, the Dow Jones U.S. Select Insurance Index. The fund primarily invests in the component securities of this index, with at least 80% of its assets dedicated to these holdings or investments that closely mimic their economic characteristics. This targeted approach ensures the fund remains aligned with the sectors performance.

While the funds core strategy revolves around tracking its index, it retains flexibility to enhance returns or manage risk. Up to 20% of its assets may be allocated to derivatives such as futures and options, cash and cash equivalents, or other securities not included in the index. These investments are selected to improve tracking accuracy or respond to market conditions, allowing the fund to adapt while staying true to its objective.

As a non-diversified fund, IAK can concentrate its holdings in a smaller number of securities, which may heighten sector-specific risks but also offers the potential for significant gains. This structure is common in sector-specific ETFs, enabling focused exposure to the insurance industrys growth prospects.

With assets under management (AUM) of $716.71 million as of October 2023, IAK is a moderately sized ETF, providing a balance between liquidity and targeted exposure. Its focus on the insurance sector includes life insurance, property and casualty, and other related financial services, making it a tool for investors seeking to capitalize on the sectors dynamics.

Looking ahead, the insurance sectors outlook will likely be shaped by interest rates and economic conditions. Rising rates can enhance insurers investment income, particularly for life insurance companies, but may also increase competition and regulatory scrutiny. Aswath Damodaran would emphasize analyzing the sectors financial health, competitive positioning, and regulatory environment to assess future prospects. While the sector faces challenges, well-positioned companies with strong balance sheets may thrive, offering opportunities for growth in a structured risk framework.

Additional Sources for IAK ETF

IAK ETF Overview

Market Cap in USD 717m
Category Financial
TER 0.40%
IPO / Inception 2006-05-01

IAK ETF Ratings

Growth 5y 91.1%
Fundamental -
Dividend 49.8%
Rel. Strength Industry -1.43
Analysts -
Fair Price Momentum 145.52 USD
Fair Price DCF -

IAK Dividends

Dividend Yield 12m 1.47%
Yield on Cost 5y 3.62%
Annual Growth 5y 6.25%
Payout Consistency 94.1%

IAK Growth Ratios

Growth Correlation 3m 47.5%
Growth Correlation 12m 84.1%
Growth Correlation 5y 97.3%
CAGR 5y 20.77%
CAGR/Max DD 5y 0.69
Sharpe Ratio 12m 1.02
Alpha 12.69
Beta 0.48
Volatility 20.49%
Current Volume 30.3k
Average Volume 20d 48.6k
What is the price of IAK stocks?
As of March 09, 2025, the stock is trading at USD 134.32 with a total of 30,347 shares traded.
Over the past week, the price has changed by -1.26%, over one month by +3.79%, over three months by +3.10% and over the past year by +21.28%.
Is iShares U.S. Insurance a good stock to buy?
Yes. Based on ValueRay Analyses, iShares U.S. Insurance (NYSE ARCA:IAK) is currently (March 2025) a good stock to buy. It has a ValueRay Growth Rating of 91.07 and therefor a clear technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IAK as of March 2025 is 145.52. This means that IAK is currently overvalued and has a potential downside of 8.34%.
Is IAK a buy, sell or hold?
iShares U.S. Insurance has no consensus analysts rating.
What are the forecast for IAK stock price target?
According to ValueRays Forecast Model, IAK iShares U.S. Insurance will be worth about 162.7 in March 2026. The stock is currently trading at 134.32. This means that the stock has a potential upside of +21.11%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 162.7 21.1%